Daniel Pertschuk

Dr. Pertschuk has spent the last 30 years working in positions of increasing responsibility in small to medium-size biotechnology companies. During this period Dr. Pertschuk has conducted Phase 1 through Phase 3 studies for a diverse group of clinical candidates that includes small molecules, monoclonal antibodies, vaccines and gene therapies. For the past 14 years Dr. Pertschuk has been closely involved in the adult, primary malignant brain tumor space; most recently at Tocagen (NASDAQ: TOCA), where he led the early-stage clinical development of the company’s treatment for glioblastoma.